Cure8 news brief
An at-home subcutaneous induction option for risankizumab could make starting Skyrizi easier and more convenient for adults with moderate-to-severe Crohn’s disease, potentially reducing the need for clinic infusions.
Adults with Crohn’s disease considering or currently on biologic therapy, patients planning treatment initiation, clinicians who prescribe/coordinate biologics, and clinic infusion services.
FDA has approved a subcutaneous (on-body injector) induction regimen for Skyrizi (risankizumab-rzaa) in adults with moderately to severely active Crohn’s disease, allowing initiation of treatment at home (720 mg via OBI at weeks 0, 2, 4, 8) followed by OBI maintenance every 8 weeks from week 12.
The existing IV induction option (600 mg at weeks 0, 4, 8) remains available. What changed: the approval enables a patient-startable at-home SC induction alternative to intravenous induction, which may reduce infusion visits.
The article is an industry news report summarizing the FDA approval; it notes dosing schedule but does not provide clinical outcome data or detailed safety discussion. Practical note: patients should discuss with their prescribing clinician whether the SC OBI induction is appropriate for them, how the device is used, and insurance/coverage implications.
This is a regulatory approval announcement (industry news). The article provides the approved dosing schedule but does not report new clinical trial results. Coverage, device training, and local access may affect whether patients can use the on-body injector.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A subcutaneous induction option means some adults with moderate–severe Crohn’s disease can begin risankizumab treatment at home rather than needing an IV infusion visit, potentially increasing convenience and access. The...
An FDA approval of a subcutaneous induction option for risankizumab means adults with moderate-to-severe Crohn's disease can start treatment at home using an on-body injector, which may make starting therapy more...
An at‑home subcutaneous induction option for Skyrizi could make starting this IL‑23 inhibitor easier for many adults with moderate‑to‑severe Crohn’s disease, reducing the need for clinic infusions and possibly improving...
